Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced its financial results for the fiscal fourth quarter and full year ended June 30, 2025, showcasing substantial revenue growth and operational advancements.
The Company focused on securing FDA 510(k) clearance to expand into the U.S. market beyond Forensic Use Only settings, with significant progress made during fiscal 2025.
Revenue in the fiscal fourth quarter increased by 16% year-on-year, driven by rising demand for drug testing cartridges and strengthened operational efficiencies.
Progress Towards FDA Clearance
INBS is actively working on securing FDA 510(k) clearance for its opiate test system for codeine in the U.S., demonstrating commitment to regulatory advancements and market expansion.
Expansion Across Key Markets
The Company experienced significant revenue growth in the fiscal fourth quarter fueled by increased sales of drug testing cartridges and strategic partnerships, with a focus on high-margin revenue streams.
Operational Efficiencies and Localization
INBS focused on enhancing operational efficiencies and localizing business strategies to strengthen its fundamentals and support sustainable growth.
- INBS achieved sequential and year-on-year revenue growth, indicating a positive trajectory in financial performance and market positioning.
- The Company's focus on securing FDA clearance and expanding into key markets contributed to revenue growth, showcasing a strategic approach to market penetration and product adoption.
- Operational improvements and strategic partnerships underscored INBS's commitment to driving growth and efficiency in its operations, laying a solid foundation for future expansion.
Intelligent Bio Solutions Inc.'s fiscal 2025 results showcase a year of growth, driven by revenue expansion, regulatory advancements, and operational enhancements. The Company's strategic priorities for fiscal 2026 aim at accelerating growth, achieving operational excellence, and expanding into the U.S. market.